ID

38775

Beskrivning

A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM); ODM derived from: https://clinicaltrials.gov/show/NCT01733758

Länk

https://clinicaltrials.gov/show/NCT01733758

Nyckelord

  1. 2019-11-03 2019-11-03 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

3 november 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Diabetes Mellitus, Type 2 NCT01733758

Eligibility Diabetes Mellitus, Type 2 NCT01733758

Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
subjects with diagnosis of type 2 diabetes mellitus, treated with diet and exercise or a stable dose of 1 oad at screening
Beskrivning

Diabetes Mellitus, Non-Insulin-Dependent | Diet therapy | Exercise | Antidiabetics Oral Quantity | Antidiabetics Dose Stable

Datatyp

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2]
C0012159
UMLS CUI [3]
C0015259
UMLS CUI [4,1]
C0935929
UMLS CUI [4,2]
C1527415
UMLS CUI [4,3]
C1265611
UMLS CUI [5,1]
C0935929
UMLS CUI [5,2]
C0178602
UMLS CUI [5,3]
C0205360
body mass index (bmi) 17 to 40 kg/ m^2 inclusive
Beskrivning

Body mass index

Datatyp

boolean

Alias
UMLS CUI [1]
C1305855
subjects who are oad naïve, hba1c between 7.0% and 10.0% at screening and at visit 2; for subjects who enter the study with 1 oad, hba1c between 6.5% and 9.5% at screening and hba1c between 7.0% and 10.0% at visit 2
Beskrivning

Antidiabetics Oral Absent | Hemoglobin A1c measurement | Antidiabetics Oral Quantity

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C1527415
UMLS CUI [1,3]
C0332197
UMLS CUI [2]
C0474680
UMLS CUI [3,1]
C0935929
UMLS CUI [3,2]
C1527415
UMLS CUI [3,3]
C1265611
creatinine clearance >30 ml/min (calculated using the cockcroft-gault formula)
Beskrivning

Estimation of creatinine clearance by Cockcroft-Gault formula

Datatyp

boolean

Alias
UMLS CUI [1]
C2711451
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of type 1 diabetes mellitus •female subject is pregnant, lactating, or <6 weeks postpartum•
Beskrivning

Diabetes Mellitus, Insulin-Dependent | Pregnancy | Breast Feeding | Postpartum Period

Datatyp

boolean

Alias
UMLS CUI [1]
C0011854
UMLS CUI [2]
C0032961
UMLS CUI [3]
C0006147
UMLS CUI [4]
C0086839
clinically significant cardiovascular and/or cerebrovascular disease
Beskrivning

Cardiovascular Disease | Cerebrovascular Disorder

Datatyp

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C0007820
current ongoing symptomatic biliary disease, clinical signs or symptoms of pancreatitis, or a history of chronic or acute pancreatitis, as determined by the investigator
Beskrivning

Gall Bladder Disease Symptomatic | Sign or Symptom Pancreatitis | Pancreatitis, Chronic | Pancreatitis

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0016977
UMLS CUI [1,2]
C0231220
UMLS CUI [2,1]
C3540840
UMLS CUI [2,2]
C0030305
UMLS CUI [3]
C0149521
UMLS CUI [4]
C0030305
serum amylase >=3 ×uln and/or serum lipase >=2 × uln and/or subject is experiencing any symptoms possibly related to pancreatitis
Beskrivning

Serum amylase raised | Serum lipase raised | Symptoms Relationship Pancreatitis

Datatyp

boolean

Alias
UMLS CUI [1]
C0476327
UMLS CUI [2]
C3670924
UMLS CUI [3,1]
C1457887
UMLS CUI [3,2]
C0439849
UMLS CUI [3,3]
C0030305
prior use of a tzd or glp-1r agonist within 4 months before screening
Beskrivning

Thiazolidinediones | GLP-1R Agonist

Datatyp

boolean

Alias
UMLS CUI [1]
C1257987
UMLS CUI [2,1]
C0378073
UMLS CUI [2,2]
C2987634

Similar models

Eligibility Diabetes Mellitus, Type 2 NCT01733758

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent | Diet therapy | Exercise | Antidiabetics Oral Quantity | Antidiabetics Dose Stable
Item
subjects with diagnosis of type 2 diabetes mellitus, treated with diet and exercise or a stable dose of 1 oad at screening
boolean
C0011860 (UMLS CUI [1])
C0012159 (UMLS CUI [2])
C0015259 (UMLS CUI [3])
C0935929 (UMLS CUI [4,1])
C1527415 (UMLS CUI [4,2])
C1265611 (UMLS CUI [4,3])
C0935929 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C0205360 (UMLS CUI [5,3])
Body mass index
Item
body mass index (bmi) 17 to 40 kg/ m^2 inclusive
boolean
C1305855 (UMLS CUI [1])
Antidiabetics Oral Absent | Hemoglobin A1c measurement | Antidiabetics Oral Quantity
Item
subjects who are oad naïve, hba1c between 7.0% and 10.0% at screening and at visit 2; for subjects who enter the study with 1 oad, hba1c between 6.5% and 9.5% at screening and hba1c between 7.0% and 10.0% at visit 2
boolean
C0935929 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0474680 (UMLS CUI [2])
C0935929 (UMLS CUI [3,1])
C1527415 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Estimation of creatinine clearance by Cockcroft-Gault formula
Item
creatinine clearance >30 ml/min (calculated using the cockcroft-gault formula)
boolean
C2711451 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Diabetes Mellitus, Insulin-Dependent | Pregnancy | Breast Feeding | Postpartum Period
Item
history of type 1 diabetes mellitus •female subject is pregnant, lactating, or <6 weeks postpartum•
boolean
C0011854 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
C0006147 (UMLS CUI [3])
C0086839 (UMLS CUI [4])
Cardiovascular Disease | Cerebrovascular Disorder
Item
clinically significant cardiovascular and/or cerebrovascular disease
boolean
C0007222 (UMLS CUI [1])
C0007820 (UMLS CUI [2])
Gall Bladder Disease Symptomatic | Sign or Symptom Pancreatitis | Pancreatitis, Chronic | Pancreatitis
Item
current ongoing symptomatic biliary disease, clinical signs or symptoms of pancreatitis, or a history of chronic or acute pancreatitis, as determined by the investigator
boolean
C0016977 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C3540840 (UMLS CUI [2,1])
C0030305 (UMLS CUI [2,2])
C0149521 (UMLS CUI [3])
C0030305 (UMLS CUI [4])
Serum amylase raised | Serum lipase raised | Symptoms Relationship Pancreatitis
Item
serum amylase >=3 ×uln and/or serum lipase >=2 × uln and/or subject is experiencing any symptoms possibly related to pancreatitis
boolean
C0476327 (UMLS CUI [1])
C3670924 (UMLS CUI [2])
C1457887 (UMLS CUI [3,1])
C0439849 (UMLS CUI [3,2])
C0030305 (UMLS CUI [3,3])
Thiazolidinediones | GLP-1R Agonist
Item
prior use of a tzd or glp-1r agonist within 4 months before screening
boolean
C1257987 (UMLS CUI [1])
C0378073 (UMLS CUI [2,1])
C2987634 (UMLS CUI [2,2])

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial